Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 21,191 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunity Disorders Clear all
Not listed No phase listed Observational

Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies

NCT02338479
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia/Lymphoma, Myelodysplasia, Acute Myelogenous Leukemia, Juvenile Myelomonocytic Leukemia, Chronic Myelogenous Leukemia
Interventions
Not listed
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
Up to 22 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
32
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 20, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available

Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma

NCT01472562
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
lenalidomide, rituximab
Drug · Biological
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
4
States / cities
Tampa, Florida • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 20, 2026, 5:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of Osteocytes in Myeloma Bone Disease

NCT02212262
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Not listed
Lead sponsor
Attaya Suvannasankha
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 20, 2026, 5:24 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706

NCT06665646
View directory record Official record
Conditions
HIV Infections
Interventions
CD40.HIVRI.Env (VRIPRO), Hiltonol Poly-ICLC-adjuvant
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
7
States / cities
San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 20, 2026, 5:24 AM EDT
Terminated Not applicable Interventional

Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients

NCT00655226
View directory record Official record
Conditions
Hepatitis C, Depressive Disorder, Major, Depressive Disorder, Depression, HIV Infections
Interventions
Hepatitis C educational support groups, Cognitive Behavioral Therapy skills based group sessions
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2011 · Synced Oct 20, 2026, 5:24 AM EDT
Terminated Phase 1 Interventional

A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma

NCT04171843
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
PBCAR269A, Fludarabine, Cyclophosphamide, Nirogacestat
Genetic · Drug
Lead sponsor
Precision BioSciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Duarte, California • San Francisco, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 20, 2026, 5:24 AM EDT
Completed Phase 2 Interventional

Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

NCT00020943
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, carmustine, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, prednisone, vincristine sulfate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 69 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
80
States / cities
Anniston, Alabama • Birmingham, Alabama • La Jolla, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 20, 2026, 5:24 AM EDT
Withdrawn Phase 2 Interventional

Lenalidomide and Obinutuzumab for Previously Untreated CLL

NCT02371590
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Lenalidomide, Obinutuzumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 20, 2026, 5:24 AM EDT
Completed Phase 1 Interventional Results available

Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis

NCT04602390
View directory record Official record
Conditions
Multiple Sclerosis (MS), Relapsing Remitting Multiple Sclerosis
Interventions
ANK-700, Placebo
Drug
Lead sponsor
Anokion SA
Industry
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
15
States / cities
Cullman, Alabama • Phoenix, Arizona • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 20, 2026, 5:24 AM EDT
Not listed Not applicable Interventional

Effect of a Fasting Mimicking Diet on Patients With Multiple Sclerosis (FMDMS)

NCT06515782
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Med Diet. Investigators would like to see what differences a Mediterranean Diet makes to the status of patients with Multiple Sclerosis.
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 20, 2026, 5:24 AM EDT
Completed Phase 2 Interventional

Intervention for Depressed Latina Mothers of Children With Asthma

NCT01326182
View directory record Official record
Conditions
Pediatric Asthma, Maternal Depression
Interventions
MAADRE, MAAS
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 20, 2026, 5:24 AM EDT
Terminated No phase listed Observational

A Natural History Study to Assess the Clinical Outcomes of Patients With Complement Factor I Deficiency-Mediated Disease

NCT05095623
View directory record Official record
Conditions
Recurrent Bacterial Infection, Autoimmune Disorder
Interventions
Natural History Observation
Other
Lead sponsor
Catalyst Biosciences
Industry
Eligibility
6 Months and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Huntsville, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 8, 2022 · Synced Oct 20, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available

Denosumab for Smoldering Multiple Myeloma

NCT03839459
View directory record Official record
Conditions
Smoldering Multiple Myeloma
Interventions
Denosumab
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 20, 2026, 5:24 AM EDT
Completed Phase 4 Interventional

A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults

NCT00004585
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine and Zidovudine, Lamivudine/Zidovudine, Abacavir sulfate, Efavirenz
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Manhasset, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 5:24 AM EDT
Not listed Phase 1 Interventional

Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer

NCT03775525
View directory record Official record
Conditions
Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach, Lymphoma, Sarcoma, Cutaneous T Cell Lymphoma, Head and Neck Squamous Cell Carcinoma, Basal Cell Carcinoma, Cutaneous T-cell Lymphoma, Cutaneous Squamous Cell Carcinoma
Interventions
GZ17-6.02, Capecitabine
Drug
Lead sponsor
Genzada Pharmaceuticals USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Scottsdale, Arizona • Los Angeles, California • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 20, 2026, 5:24 AM EDT
Active, not recruiting Phase 3 Interventional

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT01863550
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Bortezomib, Carfilzomib, Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide, Quality-of-Life Assessment
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
1,087 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2034
U.S. locations
909
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Hot Springs, Arkansas + 551 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 5:24 AM EDT
Completed Phase 2 Interventional

Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00049374
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
oblimersen sodium, dexamethasone, thalidomide
Biological · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 20, 2026, 5:24 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study

NCT03652623
View directory record Official record
Conditions
HIV/AIDS, Gender, Behavior and Behavior Mechanisms
Interventions
TDF/FTC
Drug
Lead sponsor
Hektoen Institute for Medical Research
Other
Eligibility
15 Years to 24 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Oct 20, 2026, 5:24 AM EDT
Terminated Phase 4 Interventional Results available

Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept

NCT02353780
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
TNF Antagonist (enbrel, humire, remicade, cimzia, symponi), Abatacept, Tocilizumab
Drug
Lead sponsor
Dr. Larry W. Moreland
Other
Eligibility
18 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 20, 2026, 5:24 AM EDT
Completed Phase 1 Interventional

Electrophilic Fatty Acid Derivatives in Asthma

NCT01733485
View directory record Official record
Conditions
Asthma, Electrophilic Fatty Acids
Interventions
Aspirin, Indomethacin
Drug
Lead sponsor
Sally E. Wenzel MD
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 20, 2026, 5:24 AM EDT
Active, not recruiting Phase 3 Interventional

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

NCT05985915
View directory record Official record
Conditions
Sjogrens Syndrome
Interventions
Ianalumab (VAY736), Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
32
States / cities
Fullerton, California • La Palma, California • Van Nuys, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 5:24 AM EDT
Completed Phase 3 Interventional Results available

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

NCT01545076
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy
Interventions
IgPro20 (low dose), Placebo, IgPro10, IgPro20 (high dose)
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 20, 2026, 5:24 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Harm Reduction in HIV Primary Care for PLWH Who Use Drugs

NCT05404750
View directory record Official record
Conditions
Human Immunodeficiency Virus, Substance Use, Stigma, Social
Interventions
Harm Reduction
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
641 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 20, 2026, 5:24 AM EDT
Completed No phase listed Observational

Vibration Response Imaging in Chronic Obstructive Pulmonary Disease and Asthma

NCT00542282
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Asthma
Interventions
Not listed
Lead sponsor
Deep Breeze
Industry
Eligibility
18 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2009 · Synced Oct 20, 2026, 5:24 AM EDT